NCT06655337 Efficiency of the "Medidux" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)
| NCT ID | NCT06655337 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mobile Health AG |
| Condition | Acute Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 417 participants |
| Start Date | 2025-09-28 |
| Primary Completion | 2027-03-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 417 participants in total. It began in 2025-09-28 with a primary completion date of 2027-03-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints. This trial includes adult patients (age ≥ 18) in Emergency Severity Index (ESI) triage system groups 4 (standard) or 5 (non-urgent), presenting with primary symptoms such as cough, back pain, or abdominal discomfort. The main question it aims to answer is: Can the medidux™ app reduce the incidence of AAU readmissions, emergency hospitalizations, or consultations with other medical providers within 7 days after initial admission? Researchers will compare participants using the medidux™ app (intervention arm) with those receiving standard care (control arm) to observe potential differences in the rates of readmissions, emergency hospitalizations, and medical consultations. Participants will: * use the medidux™ app to monitor their symptoms and vital parameters for 7 days after discharge (intervention arm). * receive follow-up consultations at day 7 and at day 28 to assess symptom progression and any healthcare interactions (both arms).
Eligibility Criteria
Inclusion Criteria: * Signed Informed Consent Form (ICF) * Age ≥ 18 years * (Self-)admission to the involved Acute Admissions Unit (AAU) * "Lead symptom" identified as coughing, back pain or abdominal discomfort * Participant within ESI triage system group 4 (standard) and 5 (non-urgent) * German-speaking * Ownership of a smartphone or other mobile device with iOS or Android operating system Exclusion Criteria: * Age \< 18 years * Participant whose compliance to the study's protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted * Participant with insufficient knowledge about the use of a smartphone or other mobile device with iOS or Android operating system * Participant already using or planning to use another comparable electronic patient-reported symptom monitoring system (e.g. CANKADO) during this trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06655337 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06655337 currently recruiting?
Yes, NCT06655337 is actively recruiting participants. Contact the research team at andreas.trojan@mobilehealth.ch for enrollment information.
Where is the NCT06655337 trial being conducted?
This trial is being conducted at Horgen, Switzerland.
Who is sponsoring the NCT06655337 clinical trial?
NCT06655337 is sponsored by Mobile Health AG. The trial plans to enroll 417 participants.